卵巢癌（OvCa）是目前影响妇女健康的第五种最致命的恶性肿瘤，由于缺乏早期诊断和治疗选择，直到疾病进展到晚期。紫杉醇（PTX）已经表现出对多种人类癌症，包括卵巢癌的显著抗肿瘤作用多年。尽管如此，由于表面活性剂相关毒性和非靶向效应，该药物的治疗使用尚不充分。为了应对这些限制，纳米颗粒载体已经发展为PTX的生物相容性和靶向输送工具。在这项工作中，通过前药工程和HA装饰策略，开发了一种针对OvCa细胞的新型聚合物PTX配方，实现了靶向治疗。进一步研究表明，HA包被的纳米药物（HA-PLA-PTX NPs）可以优先在表达CD44的SKOV3细胞中积累，诱导细胞毒性上升，减少细胞增殖，并增加细胞凋亡。体内研究还表明，HA-PLA-PTX NPs的等效剂量在SKOV3异种移植瘤模型中超过了临床PTX配方Taxol。总之，HA-PLA-PTX NPs可能成为有效治疗卵巢癌的潜在可行的输送系统。版权所有 ©2022作者。由Elsevier Masson SAS出版。保留所有权利。

Ovarian cancer (OvCa) is currently the fifth most lethal malignancy affecting women health owing to the lack of early diagnosis and treatment choices available before the disease has progressed to a later stage. Paclitaxel (PTX) has shown substantial antineoplastic action against a variety of human cancers, including OvCa, for multiple decades. Despite this, the therapeutic use of this drug is not yet adequate owing to surfactant-related toxicities and off-target effects. In response to these constraints, nanoparticle carriers have evolved as delivery tools for the biocompatible and target delivery of PTX. In this work, a novel polymeric PTX formulation was developed for targeted therapy of OvCa cells, which was achieved by prodrug engineering and HA decoration strategies. Further studies indicated that HA-coated nanodrugs (HA-PLA-PTX NPs) could preferentially accumulate in the CD44-expressing SKOV3 cells, which induced elevated cytotoxicity, reduced cell proliferation, and increased cell apoptosis. In vivo study also demonstrated that equivalent doses of HA-PLA-PTX NPs surpassed the clinical PTX formulation Taxol in a SKOV3 xenograft tumor model. In conclusion, HA-PLA-PTX NPs might be a potentially feasible delivery system for effective OvCa treatment.Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.